Law360, New York (June 24, 2009, 12:00 AM ET) -- The U.S. Securities and Exchange Commission has asked Matrixx Initiatives Inc. to turn over documents and information related to the U.S. Food and Drug Administration's warning that a few of the company's Zicam Cold Remedy products cause consumers to lose their sense of smell.
In a filing with the SEC on Tuesday, Matrixx said it had received an informal inquiry requesting "certain documents and information" related to the FDA's June 16 warning letter. Matrixx said it would fully cooperate with the SEC.
Matrixx said Wednesday that...
SEC Probes Matrixx Following FDA Zicam Warning
To view the full article, take a free trial now.
